AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|
30 C
New York
Thursday, July 2, 2026

Tag: development

newssourceFORcompanyinformationcontent1releasesmarket

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

IBA‑UIBC Cup of Bakers 2027 “Golden Statue Cup” China Selection – Hong Kong & Macao SAR Selection Competition Successfully Held in Hong Kong

Competition Highlights Industry Excellence and Strengthens International Exchange in the Baking Sector HONG KONG, June 7, 2026 /PRNewswire/ -- The Final of the IBA‑UIBC Cup...

Dongfeng Liuzhou Motor’s 10th “67 Brand Customer Day” Advancing New Pathways for Global Growth

LIUZHOU, China, June 7, 2026 /PRNewswire/ -- On June 7, Dongfeng Liuzhou Motor (DFLZM) hosted its 10th "67 Brand Customer Day" in Liuzhou. More than...

Dongfeng Liuzhou Motor’s 10th “67 Brand Customer Day” Advancing New Pathways for Global Growth

LIUZHOU, China, June 7, 2026 /PRNewswire/ -- On June 7, Dongfeng Liuzhou Motor (DFLZM) hosted its 10th "67 Brand Customer Day" in Liuzhou. More than...

Looney Tunes™ Land Now Open at Six Flags Magic Mountain

Complete reimagining of the park's family area offers a brand-new experience that encourages exploration across four distinct areas with loveable Looney Tunes™ characters at its heartLooney...

A New Era Begins: Cal Poly Unveils the John Madden Football Center

$45 Million Facility Honors Legendary Alumnus and Elevates the Future of Mustang FootballSAN LUIS OBISPO, Calif., June 6, 2026 /PRNewswire/ -- Cal Poly Athletics...

The American Diabetes Association Announces Winners of the Innovation Challenge

NEW ORLEANS, June 6, 2026 /PRNewswire/ -- Today, from the main stage at the organization's 2026 Scientific Sessions, the American Diabetes Association® (ADA) announced...

The Adam Foundation Commits $750,000 to the FIFA Global Citizen Education Fund, Helping Drive the Initiative Past the $50 Million Mark

Announcement made at Global Citizen Live: Rio de Janeiro ahead of the FIFA World Cup FinalLONDON, June 7, 2026 /PRNewswire/ -- The Adam Foundation,...

Communiqué Orange : Orange signs a joint agreement to acquire SFR, a decisive step that will reinforce its leadership in France

Press release
Paris, 6 June 2026

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers